Foscarnet sodium
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antiviral |
| Catalog number | BBF-05848 |
| CAS | 63585-09-1 |
| Molecular Weight | 191.95 |
| Molecular Formula | CNa3O5P |
| Purity | >98% |
Online Inquiry
Description
Foscarnet Sodium inhibits viral RNA polymerases, reverse transcriptases and DNA polymerases by non-competitive inhibition of dNTPs. It is an antiviral agent used in the treatment of cytomegalovirus retinitis. It has activity against human herpesviruses and HIV.
Specification
| Related CAS | 4428-95-9 (free acid) 34156-56-4 (hexahydrate) |
| Synonyms | Trisodium phosphonoformate; Trisodium carboxyphosphate; Foscarnet trisodium; Phosphonoformic acid trisodium salt; 1,1-Dihydroxyphosphinecarboxylic Acid 1-Oxide Sodium Salt; A 29622; EHB 776; Gefin; Triapten |
| Storage | Store at 2-8°C |
| IUPAC Name | trisodium;phosphonatoformate |
| Canonical SMILES | C(=O)([O-])P(=O)([O-])[O-].[Na+].[Na+].[Na+] |
| InChI | InChI=1S/CH3O5P.3Na/c2-1(3)7(4,5)6;;;/h(H,2,3)(H2,4,5,6);;;/q;3*+1/p-3 |
| InChI Key | DFHAXXVZCFXGOQ-UHFFFAOYSA-K |
Properties
| Appearance | White Crystal |
| Application | Antiviral Agents |
| Antibiotic Activity Spectrum | Viruses |
| Boiling Point | 270-272°C |
| Melting Point | >250°C |
| Flash Point | 270-272°C |
| Solubility | Soluble in Water (Sparingly, Heated) |
Reference Reading
1.Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
Iwami D1, Ogawa Y2, Fujita H3, Morita K1, Sasaki H1, Oishi Y1, Higuchi H1, Hatanaka K3, Shinohara N1. Nephrology (Carlton). 2016 Mar 10. doi: 10.1111/nep.12767. [Epub ahead of print]
Cytomegalovirus (CMV) infection is the most common infectious complication following solid organ transplantation. Ganciclovir (GCV)-resistant CMV infection may be fatal, and is difficult to treat whilst avoiding allograft rejection. A 31-year-old woman received a second ABO-incompatible kidney transplant, from her father. Induction therapy consisted of basiliximab and rituximab followed by maintenance immunosuppression with tacrolimus, mycophenolate mofetil, and methylprednisolone. Her CMV serostatus was D+ /R- at second transplant and she received prophylactic low-dose valganciclovir (VGCV). BK polyoma virus nephropathy (BKVN) developed 7 months after transplant concurrent with CMV hepatitis and retinitis. VGCV was increased to a therapeutic dose combined with reduced immunosuppression with minimal methylprednisolone (2 mg/day) and everolimus (0.5 mg/day). However, pp65 antigenemia continued to increase for 6 weeks. Her CMV was defined as ganciclovir (GCV)-resistant.
2.Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
Young PG1, Rubin J2, Angarone M3, Flaherty J3, Penugonda S3, Stosor V3,4, Ison MG3,4. Transpl Infect Dis. 2016 Apr 2. doi: 10.1111/tid.12537. [Epub ahead of print]
BACKGROUND: Ganciclovir-resistant cytomegalovirus (GCV-R CMV) is an emerging challenge among solid organ transplant (SOT) recipients. The literature suggests that about 1% of abdominal transplant recipients develop GCV-R CMV infection. The epidemiology and outcome of GCV-R CMV in SOT recipients who have received alemtuzumab induction is not well described.
3.Treatment of CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation.
Maffini E1,2, Giaccone L1,2, Festuccia M1,2, Brunello L1,2, Busca A1, Bruno B1,2. Expert Rev Hematol. 2016 Apr 4. [Epub ahead of print]
Despite a remarkable reduction in the past decades, cytomegalovirus (CMV) disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients remains a feared complication, still associated with significant morbidity and mortality. Today first line treatment of CMV infection/reactivation is still based on dated antiviral compounds Ganciclovir (GCV), Foscarnet (FOS) and Cidofovir (CDF) with their burdensome weight of side effects. Maribavir (MBV), Letermovir (LMV) and Brincidofovir (BDF) are three new promising anti-CMV drugs without myelosuppressive properties or renal toxic effects that are under investigation in randomized phase II and III trials. Adoptive T-cell therapy (ATCT) in CMV infection possesses a strong rationale, demonstrated by several proof of concept studies; its feasibility is currently under investigation by clinical trials. ATCT from third-party and naïve donors could meet the needs of HSCT recipients of seronegative donors and cord blood grafts.
4.Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
Iwami D1, Ogawa Y2, Fujita H3, Morita K1, Sasaki H1, Oishi Y1, Higuchi H1, Hatanaka K3, Shinohara N1. Nephrology (Carlton). 2016 Mar 10. doi: 10.1111/nep.12767. [Epub ahead of print]
Cytomegalovirus (CMV) infection is the most common infectious complication following solid organ transplantation. Ganciclovir (GCV)-resistant CMV infection may be fatal, and is difficult to treat whilst avoiding allograft rejection. A 31-year-old woman received a second ABO-incompatible kidney transplant, from her father. Induction therapy consisted of basiliximab and rituximab followed by maintenance immunosuppression with tacrolimus, mycophenolate mofetil, and methylprednisolone. Her CMV serostatus was D+ /R- at second transplant and she received prophylactic low-dose valganciclovir (VGCV). BK polyoma virus nephropathy (BKVN) developed 7 months after transplant concurrent with CMV hepatitis and retinitis. VGCV was increased to a therapeutic dose combined with reduced immunosuppression with minimal methylprednisolone (2 mg/day) and everolimus (0.5 mg/day). However, pp65 antigenemia continued to increase for 6 weeks. Her CMV was defined as ganciclovir (GCV)-resistant.
Recommended Products
| BBF-05782 | MMAE | Inquiry |
| BBF-05808 | Triptolide | Inquiry |
| BBF-03921 | Staurosporine | Inquiry |
| BBF-03816 | Milbemycin oxime | Inquiry |
| BBF-03881 | Sancycline | Inquiry |
| BBF-02618 | Oligomycin A | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
